|
WO2009013543A2
(en)
|
2007-07-25 |
2009-01-29 |
Astrazeneca Ab |
Targeted binging agents directed to kdr and uses thereof - 035
|
|
JO3375B1
(ar)
*
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
|
|
US9266938B2
(en)
|
2011-02-10 |
2016-02-23 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
CA2854153A1
(en)
|
2011-11-02 |
2013-05-10 |
Apexigen, Inc. |
Anti-kdr antibodies and methods of use
|
|
CN104650229A
(zh)
*
|
2011-11-02 |
2015-05-27 |
埃派斯进有限公司 |
抗-kdr抗体和使用方法
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
US9758591B2
(en)
|
2012-08-24 |
2017-09-12 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
|
|
HRP20181398T1
(hr)
*
|
2012-09-12 |
2018-10-19 |
Neurimmune Holding Ag |
Specifična antitijela za amiloid polipeptida humanih otočića (hiapp) i njegova upotreba
|
|
CN111423513A
(zh)
|
2014-02-06 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
白介素-2融合蛋白和其用途
|
|
US20180193456A1
(en)
*
|
2015-06-30 |
2018-07-12 |
Henlius Biotech Co., Ltd. |
Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies
|
|
MX2018016330A
(es)
|
2016-06-27 |
2020-02-17 |
Univ California |
Combinaciones para tratamiento del cáncer.
|
|
WO2018148447A1
(en)
*
|
2017-02-08 |
2018-08-16 |
Adimab, Llc |
Antibody heavy chain variable domains targeting the nkg2d receptor
|
|
EP4491234A3
(en)
|
2017-02-08 |
2025-04-09 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
BR112019017197A2
(pt)
|
2017-02-20 |
2020-04-14 |
Dragonfly Therapeutics, Inc. |
proteínas que se ligam a her2, nkg2d e cd16
|
|
CA3054067A1
(en)
|
2017-03-14 |
2018-09-20 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|
|
KR20200069364A
(ko)
|
2017-10-24 |
2020-06-16 |
마젠타 테라퓨틱스 인코포레이티드 |
Cd117+ 세포의 고갈을 위한 조성물 및 방법
|
|
WO2019084053A1
(en)
*
|
2017-10-24 |
2019-05-02 |
Magenta Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
|
|
AU2018354189A1
(en)
|
2017-10-24 |
2020-04-23 |
Crispr Therapeutics Ag |
Compositions and methods for the depletion of CD117+ cells
|
|
AU2019218125B2
(en)
|
2018-02-08 |
2025-03-13 |
Dragonfly Therapeutics, Inc. |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
PE20220278A1
(es)
|
2018-02-08 |
2022-02-25 |
Dragonfly Therapeutics Inc |
Dominios variables de anticuerpos que se dirigen al receptor nkg2d
|
|
TW201942134A
(zh)
|
2018-02-20 |
2019-11-01 |
美商蜻蜓醫療公司 |
結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
|
|
PE20210290A1
(es)
|
2018-03-21 |
2021-02-11 |
Five Prime Therapeutics Inc |
ANTICUERPOS DE UNION A VISTA A pH ACIDO
|
|
AU2019301120A1
(en)
|
2018-07-11 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
|
EA202190468A1
(ru)
|
2018-08-08 |
2021-07-06 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
KR20250112921A
(ko)
|
2018-08-08 |
2025-07-24 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
EP4146271A4
(en)
|
2020-05-06 |
2024-09-04 |
Dragonfly Therapeutics, Inc. |
PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
|
|
US12377144B2
(en)
|
2021-03-03 |
2025-08-05 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
|
|
WO2023010122A2
(en)
*
|
2021-07-29 |
2023-02-02 |
Sonoma Biotherapeutics, Inc. |
Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory t cells to treat autoimmune diseases
|